Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xanthus Pharmaceuticals Inc.

Division of Antisoma PLC

Latest From Xanthus Pharmaceuticals Inc.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008

Highlights from the Q2 2008 review of pharmaceutical and biotechnology dealmaking: Despite the dearth in biopharmaceutical financings in the quarter (total money raised was just $2 billion) acquisitions thrived with total M&A volume of $11.8 billion. And biopharma alliance activity reached $2.7 billion in potential deal value during 2008's second quarter with only a handful more deals than the first quarter, but a 43% increase in dollar volume.

Accessing Pharma Assets: Having the Right People Helps

Out-licensing will never be a top priority for pharmaceutical firms. But where a biotech has insider knowledge of a particular program or group of programs within the larger firm, out-licensing is happening--sometimes without any clawbacks at all. This activity's helping create biotechs, and also helping them leap closer to market with nearly-approved drugs.
BioPharmaceutical Medical Device

Jumpstart to Products

Discovery research is an ever more difficult investment to justify, so companies are placing greater emphasis on mining discoveries that have already been made but whose real value remains unexploited. Big Pharma, in part inhibited by habit and current infrastructure, has not moved aggressively in the new direction-but the jumpstart model now dominates small-company strategies and will increasingly translate into the rest of the industry.
BioPharmaceutical Strategy

Start-Up Previews (6/03)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Personalized Medicine, features profiles of Aureon Biosciences Corp., Favrille Inc. and Xanthus Life Sciences Inc. Plus these Start-Ups across Health Care: Cameron Health Inc., Dynogen Pharmaceuticals Inc., Functional Genetics Inc. and Tensys Medical Inc.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Xanthus Life Sciences Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Antisoma PLC
  • Senior Management
  • Richard T Dean, PhD, CEO
    Alfred Ajami, PhD, CSO
    Lister-James John, VP, Dev.
  • Contact Info
  • Xanthus Pharmaceuticals Inc.
    Phone: (617) 225-0522
    300 Technology Sq.
    Cambridge, MA 02139